Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study
Ali, R., El-Tantawi, H., Rizk, M., El-Naggar, S., Elmetwalli, A., Salama, A. (2021). Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study. EKB Journal Management System, 17(1), 59-68. doi: 10.21608/blj.2021.194378
Radi Ali; Hala Galal El-Tantawi; Mohammed El-Sayed Rizk; Sabry Ali El-Naggar; Alaa Elmetwalli; Afrah Fatthi Salama. "Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study". EKB Journal Management System, 17, 1, 2021, 59-68. doi: 10.21608/blj.2021.194378
Ali, R., El-Tantawi, H., Rizk, M., El-Naggar, S., Elmetwalli, A., Salama, A. (2021). 'Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study', EKB Journal Management System, 17(1), pp. 59-68. doi: 10.21608/blj.2021.194378
Ali, R., El-Tantawi, H., Rizk, M., El-Naggar, S., Elmetwalli, A., Salama, A. Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study. EKB Journal Management System, 2021; 17(1): 59-68. doi: 10.21608/blj.2021.194378